Guided anti-P2Y12 therapy in patients undergoing PCI: 3 systematic reviews with meta-analyses of randomized controlled trials with homogeneous design.
Simone BirocchiMatteo RocchettiAlessandro MinardiGian Marco PoddaAlessandro SquizzatoMarco CattaneoPublished in: Thrombosis and haemostasis (2023)
No GT strategy affected MB. Overall, genotype-GT but not PFT-GT reduced MACE. However, genotype-GT and PFT-GT reduced MACE in China, but not elsewhere. PFT-GT performed poorly compared to HTPR-Therapy, likely due to inaccurate identification of HTPR patients by PFT.
Keyphrases
- meta analyses
- systematic review
- patients undergoing
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- coronary artery disease
- randomized controlled trial
- prognostic factors
- acute coronary syndrome
- acute myocardial infarction
- stem cells
- mesenchymal stem cells
- antiplatelet therapy
- patient reported